Introduction

All medical subspecialties have been subject to increased scrutiny about the ways by which their financial associations with industry, such as pharmaceutical companies, may influence, or give the appearance of influencing, recommendations in review articles [1] and clinical practice guidelines [2].

Psychiatry has been at the epicenter of these concerns, in part because of high-profile cases involving ghostwriting [3],[4] and failure to report industry-related income [5], and studies highlighting conflicts of interest in promoting psychotropic drugs[6],[7].

The revised Diagnostic and Statistical Manual of Mental Disorders (DSM), scheduled for publication mid May 2013 by the American Psychiatric Association (APA), has created a firestorm of controversy because of questions about undue industry influence…